Unknown PHASE2 INTERVENTIONAL 4-arm NCT00471510

Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men

Sponsor: Neosil, Inc.

Conditions Androgenetic Alopecia

Interventions tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

Updated 5 times since 2017 Last updated: May 16, 2008 Started: May 31, 2007 Primary completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Androgenetic Alopecia and is currently ongoing. Neosil, Inc. leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neosil, Inc.

Data source: Neosil, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamburg, Germany